Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Verve Therapeutics, Inc.

Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Low Risk High Growth Stocks to Buy. Amid carrying on new studies, the ...

Eli Lilly and Company (LLY) announced the successful completion of its acquisition of Verve Therapeutics. (VERV). Verve is a Boston-based ...

Eli Lilly and Company (NYSE: LLY ) and Verve Therapeutics, Inc. (NASDAQ: VERV ) today announced that the tender offer to purchase all of the issued and outstanding shares ("Shares") of Verve's common ...

What if a heart attack and lifetime of statin drugs could be avoided with a one-time, two-hour infusion? Kiran Musunuru, a University of Pennsylvania cardiologist and leading gene-editing researcher, ...

WEDNESDAY, June 18, 2025 (HealthDay News) — Drugmaker Eli Lilly plans to buy Verve Therapeutics, a gene-editing startup, for about $1 billion upfront. The deal gives Lilly a potential new ...

Eli Lilly to buy Verve Therapeutics for $10.50 per share, with total potential payout up to $13.50 per share. The $1.3 billion deal offers a 113% premium to Verve’s 30-day average stock price.

Eli Lilly and Verve Therapeutics announced a "definitive agreement for Lilly to acquire Verve." Lilly offered $10.50 per share in cash, payable at the closing of the transaction.

Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Verve Therapeutics ...

Eli Lilly will acquire Verve for roughly $1 billion. Verve is developing a one-time gene-editing treatment for heart disease. The company's lead drug, Verve-102, targets a gene linked to high ...

Allentown, PA (18103) Today. Variable clouds with scattered showers and thunderstorms, mainly early..